BCAB insider trading
NasdaqCM HealthcareBioAtla, Inc.: insider trade history from SEC Form 4 filings.
About BioAtla, Inc.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Company website: www.bioatla.com
BCAB insider activity at a glance
FilingIQ tracks 338 insider transactions for BCAB in filings since Dec 22, 2020. The most recent transaction is dated Aug 31, 2026.
Across the full history, 21 open-market purchases
and 104 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on BCAB insider trades is 56.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest BCAB Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for BCAB?
- FilingIQ tracks 338 Form 4 insider transactions for BCAB (BioAtla, Inc.), covering filings from Dec 22, 2020 onwards. 3 of those are dated within the last 90 days.
- Are BCAB insiders net buyers or net sellers?
- Across the full Form 4 history for BCAB, 21 transactions (6%) were open-market purchases and 104 (31%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does BCAB insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is BCAB in?
- BioAtla, Inc. (BCAB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $15.15M.
Methodology & sources
Every BCAB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.